COMMUNIQUÉS West-GlobeNewswire

VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
24/03/2026
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, [...]
Beacon Behavioral Partners Welcomes Novus Neurology and SunCoast Psychiatry
24/03/2026
Partnerships Expand Access to Advanced Neurological and Psychiatric Care in Florida and Alabama BATON ROUGE, La., March 24, 2026 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners (BBP), a growing national network of [...]
Press Release Biocartis NV: Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene Signatures
24/03/2026
PRESS RELEASE - 03/24/2026, 08:00 EDT Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene Signatures Itasca, IL, US, 24 March 2026 – Today, Biocartis announced that it has entered into a [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
24/03/2026
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a [...]
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
24/03/2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action THE WOODLANDS, Texas, March 24, 2026 [...]
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
24/03/2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary [...]
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
24/03/2026
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
Addgene and Plasmidsaurus Announce Strategic Partnership to Scale Sequencing for Leading Plasmid Repository
24/03/2026
Strategic partnership to ensure delivery of scalable, cost-effective, and reliable plasmid sequencing as Addgene’s repository expands WATERTOWN, Mass. and SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- Addgene , an [...]
Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors
24/03/2026
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from Callio Therapeutics [...]
Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development
24/03/2026
MILPITAS, Calif. and THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and [...]
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
24/03/2026
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and [...]
Transactions in connection with share buy-back program
24/03/2026
Company announcement no. 6 - 26 24 March 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant
24/03/2026
March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025. Philips’ platform-based solutions [...]
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
24/03/2026
Focused on selective acquisitions of high-quality companies in strategic industrial sectors MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge 1 , a strategic [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
Press release: Availability of the Q1 2026 aide-mémoire
24/03/2026
Availability of the Q1 2026 aide-mémoire Paris, France – March 24, 2026 . Sanofi announced today the availability of its Q1 2026 aide-mémoire on the "Investors" page of the company's website: First quarter 2026 results [...]
Communiqué de presse : Mise en ligne du document «Q1 2026 aide-mémoire »
24/03/2026
Mise en ligne du document «Q1 2026 aide-mémoire » Paris, France – 24 mars 2026 . Sanofi annonce la mise en ligne de son « Q1 2026 aide-mémoire » sur la page « Investisseurs » de son site internet. Résultats du premier [...]
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
24/03/2026
First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Approval is based on positive Phase III data from multinational and Japanese studies in patients aged 12 years and [...]

Pages